Back to top
more

Haemonetics (HAE)

(Delayed Data from NYSE)

$95.27 USD

95.27
264,142

-0.46 (-0.48%)

Updated May 20, 2024 04:00 PM ET

After-Market: $95.31 +0.04 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (93 out of 248)

Industry: Medical - Products

Better trading starts here.

Zacks News

Why Is Haemonetics (HAE) Up 9.2% Since Last Earnings Report?

Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Haemonetics Strong on Plasma Unit Amid Blood Center Weakness

    Haemonetics (HAE) witnesses strong growth in Plasma franchise. Dullness in Blood Center business prevails.

      Cardiovascular Systems Posts 2-Year LIBERTY 360 Study Data

      The 24-month outcome of LIBERTY 360 study by Cardiovascular Systems (CSII) demonstrates a constant relief from major amputation across all Rutherford Classifications (RC).

        Haemonetics (HAE) Q1 Earnings & Revenues Beat Estimates

        Haemonetics' (HAE) year-over-year growth is backed by the solid execution of its multi-year turnaround strategy.

          Zacks.com highlights: Lululemon Athletica, Sirius XM Holdings, Haemonetics, Lockheed Martin and ConocoPhillips

          Zacks.com highlights: Lululemon Athletica, Sirius XM Holdings, Haemonetics, Lockheed Martin and ConocoPhillips

            Tirthankar Chakraborty headshot

            Buy These 5 Efficient Stocks for Superb Returns

            A company with a favorable efficiency level is expected to provide impressive returns as it is believed to be positively correlated with the stock's price performance.

              Haemonetics Gains on Strong Plasma, Wider Global Footprint

              Strong growth of Haemonetics' (HAE) plasma-derived biopharmaceuticals is attributable to solid end-market demand.

                Haemonetics' Plasma Momentum Solid, Margins Gain Traction

                Solid end-market demand for plasma-derived biopharmaceuticals continues to drive growth for Haemonetics (HAE).

                  Why is Haemonetics (HAE) Up 15.6% Since Its Last Earnings Report?

                  Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                    Haemonetics (HAE) Q4 Earnings Meet, Revenues Beat Estimates

                    Continued generation of new business and geographical expansion drive Haemonetics' (HAE) Q4 results.

                      Urmimala Biswas headshot

                      Medical Product Stocks May 8 Earnings List: HSIC, PEN & More

                      An important component of the broader Medical sector, the Medical Product space consistently grabs attention owing to a string of upsides.

                        Haemonetics Rides High on Plasma, Blood Center Remains Weak

                        We are optimistic about Haemonetics' (HAE) improved Plasma franchise as strong end-market demand for plasma-derived biopharmaceuticals consistently drives growth for the company.

                          SRDX or HAE: Which is a Better Medical Product Stock?

                          Here we analyze the financials and fundamental factors of Haemonetics (HAE) and Surmodics (SRDX) to decide which is a better investment option.

                            Haemonetics' Plasma Tool Enhancement Gets 510(K) Clearance

                            Haemonetics (HAE) witnesses steady growth in Plasma franchise, led by strong end-market demand for plasma-derived biopharmaceuticals.

                              Zacks.com highlights: Haemonetics, Alarm.com Holdings, Copart and inTEST

                              Zacks.com highlights: Haemonetics, Alarm.com Holdings, Copart and inTEST

                                Tirthankar Chakraborty headshot

                                Buy These 4 Efficient Stocks for Impressive Returns

                                We have considered four popular ratios in order to find efficient companies that have the potential to provide impressive returns

                                  Why Should You Add Haemonetics (HAE) to Your Portfolio Now?

                                  Market seems to be upbeat about Haemonetics' (HAE) newly-launched platform, NexSys Plasma Collection System (PCS).

                                    Cerus (CERS) Looks Good: Stock Adds 9.5% in Session

                                    Shares of Cerus (CERS) rose 9.5% on Friday

                                      Zacks.com highlights: Copart, Haemonetics, Surmodics, Alarm.com Holdings and ConocoPhillips

                                      Zacks.com highlights: Copart, Haemonetics, Surmodics, Alarm.com Holdings and ConocoPhillips

                                        Tirthankar Chakraborty headshot

                                        5 Top-Ranked Efficient Stocks to Boost Your Portfolio

                                        A company with a favorable efficiency level will provide impressive returns irrespective of market conditions

                                          Haemonetics (HAE) Up 4.2% Since Earnings Report: Can It Continue?

                                          Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                            Haemonetics (HAE) Hits a 52-Week High: What's Driving It?

                                            Haemonetics (HAE) upbeat on integration of NexSys PCS device. A raised EPS guidance buoys optimism.

                                              Medical Device Industry Outlook - February 2018

                                              Amid the concerns related to the tax reform, Congress' postponement of the medical device tax for another two years came as a huge relief to industry participants and investors.

                                                Here's Why You Must Add Haemonetics (HAE) to Your Portfolio

                                                Haemonetics (HAE) delivers strong plasma revenues, driven by a robust performance in disposables and software in the United States. Also, the market seems upbeat about this new PCS platform.

                                                  Zacks.com featured highlights include: Lululemon, Haemonetics, NVR, YY and ConocoPhillips

                                                  Zacks.com featured highlights include: Lululemon, Haemonetics, NVR, YY and ConocoPhillips